Sphingosine 1-phosphate and cancer.
There is substantial evidence that sphingosine 1-phosphate (S1P) is involved in cancer. S1P regulates processes such as inflammation, which can drive tumorigenesis; neovascularization, which provides cancer cells with nutrients and oxygen; and cell growth and survival. This occurs at multiple levels and involves S1P receptors, sphingosine kinases, S1P phosphatases and S1P lyase. This Review summarizes current research findings and examines the potential for new therapeutics designed to alter S1P signalling and function in cancer.
Pyne
Nigel J
NJ
Cell Biology Group, Strathclyde Institute of Pharmacy and Biomedical Sciences, University of Strathclyde, 27 Taylor Street, Glasgow G4 0NR, UK. n.j.pyne@strath.ac.uk
Pyne
Susan
S
D000818:Animals; D006801:Humans; D008246:Lysophospholipids / Q000378:metabolism*; D009369:Neoplasms / Q000378:metabolism* / Q000473:pathology / Q000628:therapy; D015398:Signal Transduction; D013110:Sphingosine / Q000031:analogs & derivatives* / Q000378:metabolism
D008246:Lysophospholipids; C060506:sphingosine 1-phosphate; D013110:Sphingosine